Self-Therapeutic Nanomaterials for Cancer Therapy: A Review
Source abstract
Abstract
Cancer is a commonly lethal disease that causes many deaths every year around the world. Many strategies have been applied to treat cancer, such as surgery, radiation, and chemotherapy, but all of these therapeutic approaches are limited. Nanotechnology could provide a tremendous platform to boost the efficacy of therapeutic systems from the bench to clinical applications. The current trend of using nanomaterials for therapeutic applications is limited to drug delivery and external stimuli-responsive systems. However, several nanomaterials can reduce the growth of aggressive tumors through their self-therapeutic properties. In this review, we discuss the self-therapeutic nanomaterials that can kill cancer cells without the need for any external stimulation (heat, light, radiation, or a magnetic field) or the loading of any extra therapeutic compounds. These nanomaterials can produce reactive oxygen species, act as deoxygenating agents, or produce free radicals at tumor sites. Self-therapeutic peptide-based and other organic nanomaterials that are used to inhibit multidrug resistance (MDR) proteins, e.g., P-glycoprotein (P-gp), are also discussed. This review discusses the possible mechanisms of action of self-therapeutic nanomaterials for cancer inhibition, highlighting critical and future aspects.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
PhD School in Science and Technology of Bio and Nanomaterials, Ca’ Foscari University of Venice, Venice 30170, Italy
Department of Molecular Sciences and Nanosystems, Ca’ Foscari University of Venice, Venice 30170, Italy
Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano 33081, Italy
Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste 34127, Italy
Funding
Associazione Italiana per la Ricerca sul Cancro · Ministero della Salute
References (72)
Show source-provided references
1. 10.3322/caac.2149210.3322/caac.21492 ↗
2. 10.1021/acsmedchemlett.7b0052310.1021/acsmedchemlett.7b00523 ↗
3. 10.1021/acsmedchemlett.8b0055710.1021/acsmedchemlett.8b00557 ↗
4. 10.1002/adma.20130087510.1002/adma.201300875 ↗
5. 10.2174/092986732466617083011375510.2174/0929867324666170830113755 ↗
6. 10.1039/C7TB00195A10.1039/C7TB00195A ↗
7. 10.1038/ncomms559610.1038/ncomms5596 ↗
8. 10.3389/fchem.2019.0016710.3389/fchem.2019.00167 ↗
9. 10.1007/s11427-017-9271-110.1007/s11427-017-9271-1 ↗
10. Coderre J. A. · 1992 · 43510.1007/978-1-4615-3384-9_96 ↗
11. LOCHER G. L. · Am. J. Roentgenol. · 1936 · 36 · 1
12. Kawabata S. · 2011 · 325
13. 10.1158/1078-0432.CCR-05-003510.1158/1078-0432.CCR-05-0035 ↗
14. 10.1016/j.canlet.2004.06.00110.1016/j.canlet.2004.06.001 ↗
15. 10.4155/fmc.13.3810.4155/fmc.13.38 ↗
16. 10.1634/theoncologist.8-6-50810.1634/theoncologist.8-6-508 ↗
17. 10.2174/138161281131922001210.2174/1381612811319220012 ↗
18. 10.2174/15680091179451975210.2174/156800911794519752 ↗
19. Pizzorno L. · Integr. Med. · 2015 · 14 · 35
20. 10.1007/s10552-006-0077-810.1007/s10552-006-0077-8 ↗
21. 10.2174/18715201079116228910.2174/187152010791162289 ↗
22. 10.4155/fmc.09.7110.4155/fmc.09.71 ↗
23. 10.1038/ncomms1393610.1038/ncomms13936 ↗
24. 10.1021/acsanm.9b0248610.1021/acsanm.9b02486 ↗
25. 10.1080/0192623049026089910.1080/01926230490260899 ↗
26. 10.1677/joe.0.142040710.1677/joe.0.1420407 ↗
27. 10.3390/nano904053810.3390/nano9040538 ↗
28. 10.1007/s12274-017-1635-y10.1007/s12274-017-1635-y ↗
29. 10.1093/imammb/14.3.18910.1093/imammb/14.3.189 ↗
30. 10.1007/s10555-007-9094-710.1007/s10555-007-9094-7 ↗
31. 10.2147/vhrm.2006.2.3.21310.2147/vhrm.2006.2.3.213 ↗
32. 10.1038/s41598-019-41892-w10.1038/s41598-019-41892-w ↗
33. 10.1038/nrc136910.1038/nrc1369 ↗
34. 10.1517/17425247.2011.58515510.1517/17425247.2011.585155 ↗
35. Ma J. · Cancer Res. · 2001 · 61 · 5491
36. 10.1208/s12248-012-9339-410.1208/s12248-012-9339-4 ↗
37. 10.1039/C5NR07887C10.1039/C5NR07887C ↗
38. 10.1038/nnano.2016.28010.1038/nnano.2016.280 ↗
39. 10.1021/acsami.7b0798110.1021/acsami.7b07981 ↗
40. 10.1016/j.biomaterials.2019.04.02310.1016/j.biomaterials.2019.04.023 ↗
41. 10.1016/S0014-5793(00)02197-910.1016/S0014-5793(00)02197-9 ↗
42. Szatrowski T. P. · Cancer Res. · 1991 · 51 · 794
43. 10.1021/jacs.7b0555910.1021/jacs.7b05559 ↗
44. 10.1039/C5DT01585E10.1039/C5DT01585E ↗
45. 10.1039/C5NR00706B10.1039/C5NR00706B ↗
46. 10.1016/j.biomaterials.2012.06.07610.1016/j.biomaterials.2012.06.076 ↗
47. 10.1021/acsami.5b0175810.1021/acsami.5b01758 ↗
48. 10.1021/nn300291r10.1021/nn300291r ↗
49. 10.1002/anie.20151003110.1002/anie.201510031 ↗
50. 10.1021/acsnano.5b0617510.1021/acsnano.5b06175 ↗
51. 10.1039/C6NR08784A10.1039/C6NR08784A ↗
52. 10.1021/acsnano.8b0763510.1021/acsnano.8b07635 ↗
53. 10.1016/j.jhazmat.2014.04.05410.1016/j.jhazmat.2014.04.054 ↗
54. 10.1016/j.canlet.2014.05.00210.1016/j.canlet.2014.05.002 ↗
55. 10.1002/adma.20170344410.1002/adma.201703444 ↗
56. 10.1002/adma.20150456410.1002/adma.201504564 ↗
57. 10.1002/adma.20140592610.1002/adma.201405926 ↗
58. 10.1016/S0092-8674(00)81774-210.1016/S0092-8674(00)81774-2 ↗
59. 10.1002/pro.332010.1002/pro.3320 ↗
60. 10.1021/acsnano.8b0008110.1021/acsnano.8b00081 ↗
61. 10.1021/acsami.7b0387710.1021/acsami.7b03877 ↗
62. 10.1021/acsami.6b0306410.1021/acsami.6b03064 ↗
63. 10.1080/17425247.2018.151774910.1080/17425247.2018.1517749 ↗
64. 10.1016/j.biomaterials.2019.02.02010.1016/j.biomaterials.2019.02.020 ↗
65. 10.18632/oncotarget.1899110.18632/oncotarget.18991 ↗
66. 10.1002/adma.20190405810.1002/adma.201904058 ↗
67. 10.1083/jcb.90.3.76910.1083/jcb.90.3.769 ↗
68. 10.1007/s00441010035810.1007/s004410100358 ↗
69. 10.1021/acsnano.9b0138310.1021/acsnano.9b01383 ↗
70. 10.1038/nbt.333010.1038/nbt.3330 ↗
71. 10.1039/C8NH00191J10.1039/C8NH00191J ↗
72. 10.1103/RevModPhys.35.72410.1103/RevModPhys.35.724 ↗